<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="including remdesivir (RDV), plasma exchange or cytapheresis, hydroxychloroquine, baricitinib, and" exact="lopinavir" post="(LPV), we have tried to detail the principles behind"/>
 <result pre="[5]. These compounds include drugs that alter the neurotransmitter regulation," exact="estrogen" post="receptors, kinase signal transduction, protein processing, and DNA. A"/>
 <result pre="the SARS-CoV-2 PLpro [13]. Protease Inhibitors (PIs) PIs like disulfiram," exact="lopinavir" post="(LPV), and ritonavir have shown activity against SARS and"/>
 <result pre="[13]. Protease Inhibitors (PIs) PIs like disulfiram, lopinavir (LPV), and" exact="ritonavir" post="have shown activity against SARS and MERS. Although disulfiram"/>
 <result pre="and ritonavir have shown activity against SARS and MERS. Although" exact="disulfiram" post="has been reported to inhibit the PLpro of MERS"/>
 <result pre="MERS and SARS in-vitro, it lacks clinical evidence. LPV and" exact="ritonavir" post="were considered to suppress the 3CLpro of SARS and"/>
 <result pre="and, therefore, RDV should not be used in patients with" exact="alanine" post="transaminase (ALT) levels of â‰¥5xÂ ULN (upper limit of"/>
 <result pre="the antiviral effects of RDV is reduced if co-administered with" exact="chloroquine" post="phosphate or hydroxychloroquine sulfate [16]. Multiple clinical trials are"/>
 <result pre="of RDV is reduced if co-administered with chloroquine phosphate or" exact="hydroxychloroquine" post="sulfate [16]. Multiple clinical trials are ongoing on the"/>
 <result pre="ill patients who are frequent recipients of plasma exchange [20]." exact="Chloroquine" post="Current applications: the primary indication for chloroquine and hydroxychloroquine"/>
 <result pre="plasma exchange [20]. Chloroquine Current applications: the primary indication for" exact="chloroquine" post="and hydroxychloroquine is to prevent or treat malaria and"/>
 <result pre="[20]. Chloroquine Current applications: the primary indication for chloroquine and" exact="hydroxychloroquine" post="is to prevent or treat malaria and also in"/>
 <result pre="erythematosus (SLE), antiphospholipid antibody syndrome, rheumatoid arthritis, and SjÃ¶gren's syndrome.Â" exact="Chloroquine" post="and hydroxychloroquine have been found to have anti-inflammatory, immunomodulating,"/>
 <result pre="antiphospholipid antibody syndrome, rheumatoid arthritis, and SjÃ¶gren's syndrome.Â Chloroquine and" exact="hydroxychloroquine" post="have been found to have anti-inflammatory, immunomodulating, anti-infective, antithrombotic,"/>
 <result pre="their strong antiproliferative, antimutagenic, and inhibiting autophagy capacities [24]. MOA:Â" exact="chloroquine" post="and hydroxychloroquine have several mechanisms of action. Since these"/>
 <result pre="antiproliferative, antimutagenic, and inhibiting autophagy capacities [24]. MOA:Â chloroquine and" exact="hydroxychloroquine" post="have several mechanisms of action. Since these drugs are"/>
 <result pre="fusion and inactivation of enzymes required for viral replication [25]." exact="Chloroquine" post="demonstrates broad-spectrum antiviral activity against human coronavirus HCoV-O43 and"/>
 <result pre="is a key enzyme in the synthesis of sialic acids.Â" exact="Chloroquine" post="exerts a potentÂ anti-SARS-CoV-1 effectÂ in vitro, which is"/>
 <result pre="of a cell surface receptor, the ACE2 on Vero cells." exact="Chloroquine" post="has an effect on the immune system by its"/>
 <result pre="signaling is an important step in the viral replication cycle." exact="Chloroquine" post="prevents phosphorylation of p38 MAPK in Tamm-Horsfall protein 1"/>
 <result pre="IL-1, IL-6, TNF-Î± in immune cells [26]. Principle behind use:" exact="chloroquine" post="and hydroxychloroquine are 4-aminoquinolines that are under trial for"/>
 <result pre="TNF-Î± in immune cells [26]. Principle behind use: chloroquine and" exact="hydroxychloroquine" post="are 4-aminoquinolines that are under trial for the treatment"/>
 <result pre="chloroquine, hydroxychloroquine, or these two in combination with other drugs." exact="Chloroquine" post="has been found to affect glycosylation of ACE2, the"/>
 <result pre="cells [25]. Several in-vitro studies have been done in which" exact="chloroquine" post="has acted against both RNA and DNA viruses. Some"/>
 <result pre="virus and herpes simplex virus. Coronavirus being an RNA virus," exact="chloroquine" post="has demonstrated in vitro inhibition of HCoV-229E replication in"/>
 <result pre="with the HCoV-O43 coronavirus could have been prevented by administering" exact="chloroquine" post="through the mother's milk. These studies also exhibited an"/>
 <result pre="mother's milk. These studies also exhibited an antiviral effect of" exact="chloroquine" post="on a recombinant HCoV-O43 coronavirus [26]. Currently, there are"/>
 <result pre="are several ongoing clinical trials to test the efficacy of" exact="chloroquine" post="in combination with multiple drugs.Â On April 27, 2020,"/>
 <result pre="the FDA issued a EUAÂ for the emergency use of" exact="chloroquine" post="to treat adults and adolescents who weigh 50 kg"/>
 <result pre="Dosage: in accordance with various guidelines, the effective dose of" exact="chloroquine" post="for the treatment of COVID-19 infection has been found"/>
 <result pre="challenges: there have been some concerns regarding the safety of" exact="hydroxychloroquine" post="in high doses for treatment in critically ill patients"/>
 <result pre="doses for treatment in critically ill patients with COVID-19 [30]." exact="Hydroxychloroquine" post="can cause serious cutaneous adverse reactions, fulminant hepatic failure,"/>
 <result pre="likeÂ QTc (corrected Q-T interval) prolongation especially when prescribed with" exact="azithromycin" post="[25]. Routine electrocardiogram (ECG) is therefore recommended before starting"/>
 <result pre="and moxifloxacin; LPV/ritonavir and RDV should be avoided. Administration of" exact="hydroxychloroquine" post="and chloroquine requires frequent monitoring of complete blood count,"/>
 <result pre="LPV/ritonavir and RDV should be avoided. Administration of hydroxychloroquine and" exact="chloroquine" post="requires frequent monitoring of complete blood count, which includes"/>
 <result pre="(MI), and QTc of &amp;gt;500 msec [28]. Lopinavir Current application:" exact="lopinavir" post="(LPV) is an HIV-1 protease inhibitor administered in fixed-dose"/>
 <result pre="is an HIV-1 protease inhibitor administered in fixed-dose combination with" exact="ritonavir" post="(LPV/r). Ritonavir is a potent cytochrome P450 3A4 (CYP3A4)"/>
 <result pre="HIV-1 protease inhibitor administered in fixed-dose combination with ritonavir (LPV/r)." exact="Ritonavir" post="is a potent cytochrome P450 3A4 (CYP3A4) inhibitor, which"/>
 <result pre="of hepatotoxicity, hence close laboratoryÂ monitoring may be needed. With" exact="ritonavir" post="being a CYP3A4 inhibitor, it is also a moderate"/>
 <result pre="cases of COVID-19. Baricitinib therapy also increases the levels of" exact="creatine" post="kinase, and this elevation is more common in patients"/>
 <result pre="efficacy of baricitinib against COVID-19 is still under study [43]." exact="Ribavirin" post="Ribavirin is a guanosine analog that interferes with viral"/>
 <result pre="of baricitinib against COVID-19 is still under study [43]. Ribavirin" exact="Ribavirin" post="is a guanosine analog that interferes with viral RNA"/>
 <result pre="shown that while SARS-CoV, MERS-CoV, and HCoV-OC43 were sensitive to" exact="ribavirin" post="in vitro, drug concentrations that significantly impede CoV replication"/>
 <result pre="humans. A reason for the decreased in vitro efficacy of" exact="ribavirin" post="was found to be the excision of ribavirin nucleoside"/>
 <result pre="efficacy of ribavirin was found to be the excision of" exact="ribavirin" post="nucleoside analogs by coronavirus proofreading mechanism. Subsequent in vivo"/>
 <result pre="proofreading mechanism. Subsequent in vivo testing showed that monotherapy with" exact="ribavirin" post="showed restricted activity against SARS-CoV in mouse models. However,"/>
 <result pre="in primate models, improvement of MERS symptoms was seen when" exact="ribavirin" post="was combined with type I Interferons [44]. In a"/>
 <result pre="also demonstrated that the SARS-CoV-2 RdRpÂ model is targeted by" exact="ribavirin" post="[45]. Angiotensin-Converting Enzyme Inhibitor (ACEI) [Renin-Angiotensin System (RAS) Drugs]"/>
 <result pre="ID No. of participants* Duration Phase Sponsor Combination drugs Drug:Â" exact="hydroxychloroquine" post="+ intravenous famotidine NCT04370262 1170 April 2020â€&quot; April 2021"/>
 <result pre="participants* Duration Phase Sponsor Combination drugs Drug:Â hydroxychloroquine + intravenous" exact="famotidine" post="NCT04370262 1170 April 2020â€&quot; April 2021 Phase 3 Northwell"/>
 <result pre="4 National University of Ireland, Galway, Ireland Drug: lopinavir/ritonavir; drug:" exact="hydroxychloroquine" post="sulfate; drug: losartan; drug: placebos NCT04328012 4000 April 2020â€&quot;April"/>
 <result pre="2020â€&quot;June 2021 Phase 2, phase 3 University of Oxford Drug:" exact="hydroxychloroquine" post="sulfate tablets; drug: lopinavir/ritonavir oral tablet; drug: hydroxychloroquine sulfate"/>
 <result pre="Oxford Drug: hydroxychloroquine sulfate tablets; drug: lopinavir/ritonavir oral tablet; drug:" exact="hydroxychloroquine" post="sulfate tablets plus lopinavir/ritonavir oral tablets; drug: placebo NCT04403100"/>
 <result pre="1968 June 2020â€&quot;November 2020 Phase 3 Cardresearch Drug: hydroxychloroquine; drug:" exact="azithromycin" post="NCT04334382 1550 April 2020â€&quot;December 2021 Phase 3 Intermountain Health"/>
 <result pre="2021 Phase 3 Intermountain Health Care, Inc. Drug: hydroxychloroquine; drug:" exact="azithromycin" post="(Azithro); drug: placebo for hydroxychloroquine; drug: placebo for azithromycin"/>
 <result pre="drug: azithromycin (Azithro); drug: placebo for hydroxychloroquine; drug: placebo for" exact="azithromycin" post="NCT04358068 2000 May 2020â€&quot;March 2021 Phase 2 National Institute"/>
 <result pre="mg + 1200 mg) combined with azithromycin; drug: hydroxychloroquine; drug:" exact="hydroxychloroquine" post="combined with azithromycin NCT04411433 1000 May 2020â€&quot;July 2020 Phase"/>
 <result pre="mg) combined with azithromycin; drug: hydroxychloroquine; drug: hydroxychloroquine combined with" exact="azithromycin" post="NCT04411433 1000 May 2020â€&quot;July 2020 Phase 3 Ministry of"/>
 <result pre="May 2020â€&quot;July 2020 Phase 3 Ministry of Health, Turkey Drug:" exact="hydroxychloroquine" post="- daily dosing; drug: hydroxychloroquine - weekly dosing NCT04341441"/>
 <result pre="Ministry of Health, Turkey Drug: hydroxychloroquine - daily dosing; drug:" exact="hydroxychloroquine" post="- weekly dosing NCT04341441 3000 April 2020â€&quot;April 2021 Phase"/>
 <result pre="April 2020â€&quot;April 2021 Phase 3 Henry Ford Health System Drug:" exact="hydroxychloroquine" post="NCT04363827 2300 May 2020â€&quot;March 2021 Phase 2 Istituto Scientifico"/>
 <result pre="Romagnolo per lo Studio e la Cura dei Tumori Drug:" exact="hydroxychloroquine" post="sulfate; drug: ascorbic acid NCT04328961 2000 March 2020â€&quot;October 2020"/>
 <result pre="disoproxil; drug: hydroxychloroquine; drug: placebo: emtricitabine/tenofovir disoproxil placebo; drug: placebo:" exact="hydroxychloroquine" post="NCT04334928 4000 April 2020â€&quot;July 2020 Phase 3 Plan Nacional"/>
 <result pre="Dietary supplement: vitamins; drug: hydroxychloroquine; drug: imatinib; drug: favipiravir; drug:" exact="telmisartan" post="NCT04356495 1057 July 2020â€&quot;January 2021 Phase 3 University Hospital,"/>
 <result pre="2020 Phase 3 Montreal Heart Institute Darunavir Drug: darunavir and" exact="cobicistat" post="NCT04252274 30 January 2020â€&quot;December 2020 Phase 3 Shanghai Public"/>
 <result pre="LLC Arbidol Drug: carrimycin; drug: lopinavir/ritonavir tablets or Arbidol or" exact="chloroquine" post="phosphate; drug: basic treatment NCT04286503 520 February 2020â€&quot;February 2021"/>
 <result pre="for investigational COVID-19 convalescent plasma82020ResearchResearch2020https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma 24Current and future use of" exact="chloroquine" post="and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases:"/>
 <result pre="COVID-19 convalescent plasma82020ResearchResearch2020https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma 24Current and future use of chloroquine and" exact="hydroxychloroquine" post="in infectious, immune, neoplastic, and neurological diseases: a mini-reviewClin"/>
 <result pre="neoplastic, and neurological diseases: a mini-reviewClin Drug InvestigPlantoneDKoudriavtsevaT653671382018 25Chloroquine and" exact="hydroxychloroquine" post="in covid-19BMJFernerREAronsonJK03692020 26New insights on the antiviral effects of"/>
 <result pre="hydroxychloroquine in covid-19BMJFernerREAronsonJK03692020 26New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?Int J Antimicrob"/>
 <result pre="27FDA: coronavirus (COVID-19) update: FDA revokes emergency use authorization for" exact="chloroquine" post="and hydroxychloroquine82020CommissionerO2020https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and 28Chloroquine and hydroxychloroquine in the treatment of"/>
 <result pre="revokes emergency use authorization for chloroquine and hydroxychloroquine82020CommissionerO2020https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and 28Chloroquine and" exact="hydroxychloroquine" post="in the treatment of COVID-19 with or without diabetes:"/>
 <result pre="and other developing countriesDiabetes Metab SyndrSinghAKSinghAShaikhASinghRMisraA24124614202032247211 29Finding the dose for" exact="hydroxychloroquine" post="prophylaxis for COVID-19: the desperate search for effectiveness (Epub"/>
 <result pre="Pharmacol TherAl-KofahiMJacobsonPBoulwareDRet al.2020 30Effect of high vs low doses of" exact="chloroquine" post="diphosphate as adjunctive therapy for patients hospitalized with severe"/>
 <result pre="treated with multiple drugs. (Article in Italian)Infez MedSabbataniSLegnaniGFulgaroC1824112003https://www.infezmed.it/index.php/article?Anno=2003&amp;amp;numero=1&amp;amp;ArticoloDaVisualizzare=Vol_11_1_2003_1812719666 32Why are" exact="lopinavir" post="and ritonavir effective against the newly emerged coronavirus 2019?"/>
 <result pre="multiple drugs. (Article in Italian)Infez MedSabbataniSLegnaniGFulgaroC1824112003https://www.infezmed.it/index.php/article?Anno=2003&amp;amp;numero=1&amp;amp;ArticoloDaVisualizzare=Vol_11_1_2003_1812719666 32Why are lopinavir and" exact="ritonavir" post="effective against the newly emerged coronavirus 2019? Atomistic insights"/>
</results>
